These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 19373440)

  • 1. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
    Snider KL; Maitland ML
    Target Oncol; 2009 Apr; 4(2):67-76. PubMed ID: 19373440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
    Girardi F; Franceschi E; Brandes AA
    Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
    Vaklavas C; Lenihan D; Kurzrock R; Tsimberidou AM
    Oncologist; 2010; 15(2):130-41. PubMed ID: 20139170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of adverse effects of anti-VEGF therapy for cancer.
    Kamba T; McDonald DM
    Br J Cancer; 2007 Jun; 96(12):1788-95. PubMed ID: 17519900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
    Bose D; Meric-Bernstam F; Hofstetter W; Reardon DA; Flaherty KT; Ellis LM
    Lancet Oncol; 2010 Apr; 11(4):373-82. PubMed ID: 20171141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal toxicity of targeted therapies.
    Kelly RJ; Billemont B; Rixe O
    Target Oncol; 2009 Apr; 4(2):121-33. PubMed ID: 19421832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From theoretical synergy to clinical supra-additive toxicity.
    Soria JC; Massard C; Izzedine H
    J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
    Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting angiogenesis in bladder cancer.
    Elfiky AA; Rosenberg JE
    Curr Oncol Rep; 2009 May; 11(3):244-9. PubMed ID: 19336017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse effects of anticancer agents that target the VEGF pathway.
    Chen HX; Cleck JN
    Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S23-30. PubMed ID: 17239287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs.
    Prescrire Int; 2009 Aug; 18(102):165. PubMed ID: 19746526
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
    J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral drugs inhibiting the VEGF pathway].
    Ropert S; Mir O; Armand JP
    Bull Cancer; 2007 Jul; 94 Spec No():S180-90. PubMed ID: 17846003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
    Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.